Department of Neuroscience, University of Turin Medical School and National Institute of Neuroscience (INN), Turin, Italy.
Nat Med. 2011 Oct 2;17(10):1228-30. doi: 10.1038/nm.2435.
Placebo analgesia is mediated by both opioid and nonopioid mechanisms, but so far nothing is known about the nonopioid component. Here we show that the specific CB1 cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (rimonabant or SR141716) blocks nonopioid placebo analgesic responses but has no effect on opioid placebo responses. These findings suggest that the endocannabinoid system has a pivotal role in placebo analgesia in some circumstances when the opioid system is not involved.
安慰剂镇痛是由阿片类和非阿片类机制介导的，但到目前为止，对于非阿片类成分还一无所知。在这里，我们表明，特异性 CB1 cannabinoid 受体拮抗剂 5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-N-(哌啶-1-基)-1H-吡唑-3-甲酰胺（利莫那班或 SR141716）阻断非阿片类安慰剂镇痛反应，但对阿片类安慰剂反应没有影响。这些发现表明，在内源性大麻素系统在某些情况下不涉及阿片类系统时，在一些情况下，内源性大麻素系统在安慰剂镇痛中起着关键作用。
